Reuters logo
in 2 months
BRIEF-Madrigal Pharmaceuticals says DSMC for clinical studies of MGL-3196 held a pre-scheduled meeting to review data from Phase 2 clinical nash trial
June 1, 2017 / 10:24 AM / in 2 months

BRIEF-Madrigal Pharmaceuticals says DSMC for clinical studies of MGL-3196 held a pre-scheduled meeting to review data from Phase 2 clinical nash trial

1 Min Read

June 1 (Reuters) - Madrigal Pharmaceuticals Inc

* Madrigal Pharmaceuticals - ‍on May 26, DSMC for clinical studies of co's MGL-3196 held a pre-scheduled meeting to review data from Phase 2 clinical nash trial

* Madrigal Pharmaceuticals - ‍DSMC recognized co for progress on clinical trial and recommended co continue clinical trial with no changes to protocol

* Madrigal Pharmaceuticals Inc - intends to proceed with clinical trial in accordance with DSMC's recommendation​

* Madrigal Pharmaceuticals Inc - ‍expects to have top-line results for primary endpoint of study, reduction of liver fat, at 12 weeks, by year-end 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below